Posts for Ticker ‘CADX’

Top 10 Analyst Upgrades, Downgrades, Initiations (CADX, COH, DELL, HTE, JWN, RIMM, S, STP, URI, VRSK)

These are the top ten analyst upgrades, downgrades, and initiations we have seen from Wall Street research calls early this Monday:

Cadence Pharmaceuticals (NASDAQ: CADX) Cut to Perform at Oppenheimer.
Coach Inc. (NYSE: COH) Raised to Buy at Goldman Sachs.
Dell Inc. (NASDAQ: DELL) Started as Buy with $19 target at Goldman Sachs.
Harvest Energy (NYSE: HTE) Cut to Neutral at UBS.
Nordstrom (NYSE: JWN) Raised to Buy at Goldman Sachs.
Research In Motion (NASDAQ: RIMM) Started as Hold, $66 target, at Auriga.
Sprint Nextel (NYSE: S) Raised to Outperform at Credit Suisse.
Suntech Power Holdings Co. Ltd. (NYSE: STP) Raised to Neutral (from Underweight) at HSBC.
United Rentals (NYSE: URI) Raised to Outperform at Oppenheimer.
Verisk Analytics (NASDAQ: VRSK) Started as In-Line at Fox-Pitt; Started as Market Perform at KBW.

You can join our open email distribution list which goes out several times per week to be notified of key analyst calls, top early morning day trader alerts, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: November 16, 2009 – 8:13 am in Analyst Calls, Technology Companies, Trading Alert, , , , , , , , , ,

Top Day Trader Alerts (ANF, RINO, CADX, TSTC, PLA, JWN)

These are this morning’s top day trader and active trader alert stocks.  More detailed analysis and data has been offered via a link to each story at VSInvestor.com:

Abercrombie & Fitch Co. (NYSE: ANF) is trading higher by 6% despite poor sales.

RINO International Corp. (NASDAQ: RINO) is hitting new 52-week highs after strong earnings.

Cadence Pharmaceuticals Inc. (NASDAQ: CADX) is down 6% after the FDA extended the review for its painkiller Acetavance.

Telestone Technologies Corp. (NASDAQ: TSTC) is the top percentage gainer.

Playboy Enterprises Inc. (NYSE: PLA) is up again 8% after yesterday’s takeover chatter.

Nordstrom Inc. (NYSE: JWN) is down about 5% on soft earnings despite raised guidance.

You can join our open email distribution list which goes out several times per week to be notified of key merger news, key analyst calls, top early morning day trader alerts, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON OGG

Posted on: November 13, 2009 – 8:53 am in Pre-Market Activity, Trading Alert, , , , , ,

Top Day Trader Alerts (AIG, AONE, MBI, PALM, SIGM, REGN, CADX, TRA, CF, AGU, BRCD)

These are this morning’s top day trader and active trader alerts seen in the pre-market trading hours.  We also included some options color from yesterday.  A link has been provided for more detailed analysis and data for each stock over at VSInvestor.com:

American International Group, Inc. (NYSE: AIG) is down only about 2% after reports that the company could find itself leaderless again.

A123 Systems, Inc. (NASDAQ: AONE) is trading down 3% after earnings and concerns over a partnership.

MBIA Inc. (NYSE: MBI) is trading up over 3% this morning after getting crushed yesterday, M.J. Whitman’s Third Avenue took a stake.

Palm Inc. (NASDAQ: PALM) is running over 3% on an analyst call.

Sigma Designs, Inc. (NASDAQ: SIGM) is down 8% on a downgrade.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading up 10% after Sanofi-Aventis expanded its antibody pact substantially.

We have many options on watch as well:

  • Cadence Pharmaceutical Inc. (NASDAQ: CADX) is one to watch with a huge binary volatility trade ahead of the 11/13 PDUFA date for Acetavance as a treatment for acute pain.
  • There was some interesting options trading seen yesterday in the trifecta fertilizer merger war via Terra Industries Inc. (NYSE: TRA), CF Industries (NYSE: CF), and Agrium (NYSE: AGU).
  • Brocade Communications Systems, Inc. (NASDAQ: BRCD) gave a stock and option alert yesterday, but it went even more active in options with the NOV09 $9 CALLS seeing 24,450 contracts and the NOV09 $10 CALLS seeing 17,432 contracts.

You can join our open email distribution list which goes out several times per week to be notified of key merger news, key analyst calls, top early morning day trader alerts, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: November 11, 2009 – 9:09 am in Pre-Market Activity, Trading Alert, , , , , , , , , , ,

Biotech Busine$$ Daily (ALKS, CADX, CVTX, MNKD, GNBT, PPHM)

Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for treatment of bipolar disorder chronic relapse. The drug was already approved for treatment of schizophrenia in 2003. Shares of Alkermes are down to by $0.17 to $10.94 in mid-day trading on a 52-week range of $10.32 to $18.78.

Cadence Pharmaceuticals Inc. (NASDAQ: CADX) up over 8% today on no new developments to $6.74 off a 52-week range of $4.84 to $20.67. Cadence Pharmaceuticals is a development stage biopharmaceutical company with two products in Phase III testing, Acetavance and Omigard.

CV Therapeutics (NASDAQ: CVTX) down today despite FDA approval for its coronary artery treatment, Lexiscan, granted last Friday. The drug is injected into patients during heart tests that cannot exercise to increase blood flow in their arteries. The drug will be marketed by OTC company Astellas Pharma US Inc. and will pay CV Therapeutics $12 million now that drug has been approved. CV Therapeutics is down over 5% to $7.57 on a 52-week range of $5.41 to $13.74.

Mannkind Corp. (NASDSQ: MNKD) still slipping today on Pfizer’s insulin scare earlier this month. Pfizer markets an inhaled insulin product, Exubera, that recently studies showed it be connected with lung cancer in its users. Despite the failings of Pfizer’s inhaled insulin product and other developers of similar treatments (including Alkermes above), Mannkind intends to continue developing its similar product, Technosphere. Shares are down almost 7% to $2.33 today on a 52-week range of $2.15 to $15.65. Pfizer (NYSE: PFE) up marginally today to $20.53 on a 52-week range of $20.19 to $27.73.

Generex Biotechnology Corp. (NASDAQ: GNBT) could benefit from Pfizer’s and Mannkind’s struggles with inhaled insulin treatments. Generex’s product Oral-lyn is viewed as a competing oral insulin product that is safe and effective. Shares are up over 2% to $1.18 today on a 52-week range of $0.81 to $2.14.

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) down almost 11% today after they announced that the pre-clinical study of their anti-PS Vascular Targeting Antibodies showed a broad range of potential for cancer treatment at the American Association of Cancer Research annual meeting. Shares are down to $0.44 on a 52-week range of $0.35 to $1.40.

Rachel Lopez
April 14, 2008

Posted on: April 14, 2008 – 12:16 pm in Biotech, , , , , ,

Cadence Pharmaceuticals (CADX): Another Biotech Implosion

Shares in Cadence Pharmaceuticals (CADX) are off as much as 50% on news that one of its drugs had failed in trials. According to Reuters "the biopharmaceutical company said one trial did not meet its main goal of significantly reducing pain following abdominal gynecologic surgery, while the other trial met its primary target of a significant reduction of fever."

The company loses about $10 million a quarter on no revenue. At the end of the third quarter it has $56 million in cash. Not much runway

Douglas A. McIntyre

Posted on: January 11, 2008 – 9:36 am in Uncategorized,